1 completed, 1 not yet recruiting, 1 terminated. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow BIO101: new trials by email Literature Review of BIO101 trials Research Report on BIO101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss. BIO101, Placebo, Semaglutide - Muscle Wasting, Obesity & Overweight | Phase 2 | Not yet recruiting | Biophytis | 164 | 2026-07-01 | 2026-02-13 |
| Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 Patients BIO101, Placebo - Covid-19, SARS-CoV2 | Phase 2 / Phase 3 | Terminated | Biophytis | 238 | 2020-08-26 | 2026-08-12 |
| A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT) BIO101, Placebo - Sarcopenia, Gait Disorders in Old Age | Phase 2 | Completed | Biophytis | 233 | 2017-02-07 | 2024-10-01 |
COVID-19 (1) · Muscle Weakness (1) · Muscular Atrophy (1) · Obesity (1) · Overweight (1) · Sarcopenia (1)
Biophytis (3)
Belgium (2) · United States (2) · Brazil (1) · France (1) · Puerto Rico (1)
Capucine Morelot-Panzini, MD (1) · Rob Van Maanen (1)